Bio Cheetah

Member Name

BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDxᵀᴹ IN JAPAN

BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDxᵀᴹ IN JAPAN

December 15, 2023

BIOCHEETAH ANNOUNCES EXCLUSIVE LICENSING AND COMMERCIALISATION AGREEMENT WITH NIPPON KAYAKU FOR VECanDxᵀᴹ IN JAPAN December 15th, 2023 Singapore and Japan – BioCheetah Pte. Ltd. (Head Office: Singapore; CEO: Dr. Lee Kian Chung; hereinafter “BioCheetah”) and Nippon Kayaku Co., Ltd. (Head Office: Tokyo; President: Mr. Atsuhiro Wakumoto; hereinafter “Nippon Kayaku”) announce that the two companies have […]

READ MORE
We are pleased to announce our strategic partnership with Wellesta for commercializing VECanDx™ ELISA test for early detection of bladder cancer.

We are pleased to announce our strategic partnership with Wellesta for commercializing VECanDx™ ELISA test for early detection of bladder cancer.

September 26, 2023

Wellesta and BioCheetah have signed an agreement whereby Wellesta will be commercializing BioCheetah’s unique, patented and biomarker-based test kit, VECanDx™ ELISA test for early detection of bladder cancer. This product will be sold, marketed and distributed in ASEAN, Indian sub-continent, MENA, EU and LATAM. BioCheetah’s VECanDx™ ELISA test is a non-invasive test used to detect […]

READ MORE
BioCheetah receives ISO 13485:2016 certification for Medical Device Design and Development

BioCheetah receives ISO 13485:2016 certification for Medical Device Design and Development

September 15, 2021

BioCheetah announces today that it has received the ISO 13485:2016 certification for Medical Device and Quality Management Systems for its facility in Singapore. BioCheetah has obtained this reputable certification from TÜV SÜD, one of the world’s leading inspection organizations on safety, security, and sustainability solutions. ISO 13485:2016 is an internationally recognized standard of quality and […]

READ MORE
Promising clinical trials aims to detect bladder cancer via a quick liquid biopsy test

Promising clinical trials aims to detect bladder cancer via a quick liquid biopsy test

May 20, 2020

Bladder cancer is the 10th most common form of cancer worldwide in both genders and appears as sixth most common cancer in men, with a respective incidence and mortality rates of 9.6 and 3.2 per 100,000 in men. In 2018, more than half a million people were diagnosed with bladder cancer and 200,000 died from […]

READ MORE
BioCheetah clinched two awards at the Asian Entrepreneurship Awards 2019

BioCheetah clinched two awards at the Asian Entrepreneurship Awards 2019

January 24, 2020

The Asian Entrepreneurship Award (AEA) 2019 was held from October 30 to November 1 in the Kashiwa-no-ha area in Kashiwa, Chiba, Japan. In the annual pitch competition, startups from 14 countries/regions in Asia were evaluated against the criteria of innovations, commercial viability and social impacts, business capability, and the potential for collaboration with Japanese companies. […]

READ MORE